Photobiomodulation therapy (PBMT) uses light to influence the mitochondria of cells. PBMT of the brain enhances the metabolic capacity of neurons and stimulates anti-inflammatory, anti-apoptotic, and antioxidant responses, as well as neurogenesis and synaptogenesis. Its therapeutic role in disorders such as dementia and Parkinson's disease, as well as to treat stroke, brain trauma, and depression has gained increasing interest. BioFlex is a form of PBMT consisting of light-emitting diodes (LEDs) and laser diodes. BioFlex utilizes red and near infrared light which penetrates tissues up to a certain tissue depth and studies have shown stimulates tissue growth and repair at the cellular level. PBMT has been proven useful for the treatment of soft tissue pain. Several studies have shown benefit in using PBMT in the treatment of certain neurological conditions, including chronic, mild traumatic brain injury (mTBI). The purpose of this exploratory investigation, therefore, is to examine efficacy of BioFlex laser therapy on measures of brain function in patients suffering from PCS after mild-moderate, closed-head, traumatic brain injury cases.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
19
The device consists of a laptop computer preprogrammed with the Bioflex® Practitioner+ Software, the Bioflex® DUO 180+ array pad that has 180 bicolour Light Emitting Diodes (LED) that emit red and near infrared light, and two laser probes, the LD-R 100 that emits red light, and the LD-I 200 that emits near infrared light.
Control
Center for Neurology Studies
Surrey, British Columbia, Canada
Meditech Rehabilitation Centre
Etobicoke, Ontario, Canada
Response size of selected ERPs (N100, P300, N400) acquired using the NeuroCatch Platform 2
Event-related potentials (ERPs)
Time frame: Visit 1/Baseline to Visit 3/End of Treatment (8 weeks)
Response timing of selected ERPs (N100, P300, N400) acquired using the NeuroCatch Platform 2
Event-related potentials (ERPs)
Time frame: Visit 1/Baseline to Visit 3/End of Treatment (8 weeks)
Number of adverse events
Frequency and severity of adverse events
Time frame: Visit 1/Baseline to Visit 3/End of Treatment (8 weeks)
Number of adverse device effects
Frequency and severity of adverse device effects
Time frame: Visit 1/Baseline to Visit 3/End of Treatment (8 weeks)
Pain Catastrophizing Scale Score
Mean, standard deviation, and assessment of variance. It is a 13-item scale, with a total range of 0 to 52. Higher scores are associated with higher amounts of pain catastrophizing.
Time frame: Visit 1/Baseline to Visit 3/End of Treatment (8 weeks)
Rivermead Post-Concussion Symptoms Questionnaire Score
Mean, standard deviation, and assessment of variance. Scored on a scale of 0-64 where higher scores reflect greater severity of post concussive symptoms.
Time frame: Visit 1/Baseline to Visit 3/End of Treatment (8 weeks)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.